Loading organizations...
§ Private Profile · San Diego, CA, USA
Biotechnology company developing novel small molecule medicines targeting metalloenzymes for oncology and infection.
Based in San Diego, California, Forge Therapeutics is a biotechnology company that develops novel small molecule medicines targeting metalloproteins to treat multidrug resistant bacteria, infectious diseases, and oncology. Founded in 2015 by Zachary Zimmerman and David Puerta, the organization operates with one to seven employees and has secured over twenty five million dollars in total venture and federal grant funding. Following a definitive merger agreement with Blacksmith Medicines in January 2023, the combined entity advances its bioinorganic chemistry platform to generate milestone and royalty revenue. Operating under this partnered business model, the enterprise successfully reported twenty nine million dollars in total revenue during the 2024 fiscal year. Through these partnered programs and financing rounds, the company collaborates with prominent pharmaceutical corporations and institutional investors, which include Roche, Eli Lilly, Basilea, Evotec, and Alexandria Venture Investments.
Forge Therapeutics has raised $26.1M across 2 funding rounds.
Forge Therapeutics has raised $26.1M in total across 2 funding rounds.
Forge Therapeutics has raised $26.1M in total across 2 funding rounds.
Forge Therapeutics's investors include Brian T. Dorsey, Jonathan Kabakoff, Mario Polywka, Jeffrey Moore, Red Apple Group, WS Investments.
Forge Therapeutics has raised $26.1M across 2 funding rounds. Most recently, it raised $11.1M Other Equity in January 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 3, 2019 | $11.1M Venture Round | — | — | Announced |
| Apr 25, 2017 | $15M Series A | Brian T. Dorsey | Jonathan Kabakoff, Mario Polywka, Jeffrey Moore, RED Apple Group, WS Investments | Announced |